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Abstract
Background: Type 2 Diabetes (T2D) is associated with increased risk of dementia. We aimed to determine the
feasibility of a randomised controlled trial (RCT) examining the efficacy of exercise on cognition and brain structure
in people with T2D.
Methods: A 6-month pilot parallel RCT of a progressive aerobic- and resistance-training program versus a gentle
movement control group in people with T2D aged 50–75 years (n = 50) at the University of Tasmania, Australia.
Assessors were blinded to group allocation. Brain volume (total, white matter, hippocampus), cortical thickness and
white matter microstructure (fractional anisotrophy and mean diffusivity) were measured using magnetic resonance
imaging, and cognition using a battery of neuropsychological tests. Study design was assessed by any changes (during
the pilot or recommended) to the protocol, recruitment by numbers screened and time to enrol 50 participants;
randomisation by similarity of characteristics in groups at baseline, adherence by exercise class attendance; safety by
number and description of adverse events and retention by numbers withdrawn.
Results: The mean age of participants was 66.2 (SD 4.9) years and 48% were women. There were no changes to the
design during the study. A total of 114 people were screened for eligibility, with 50 participants with T2D enrolled over
8 months. Forty-seven participants (94%) completed the study (23 of 24 controls; 24 of 26 in the intervention group).
Baseline characteristics were reasonably balanced between groups. Exercise class attendance was 79% for the
intervention and 75% for the control group. There were 6 serious adverse events assessed as not or unlikely
to be due to the intervention. Effect sizes for each outcome variable are provided.
Conclusion: This study supports the feasibility of a large scale RCT to test the benefits of multi-modal
exercise to prevent cognitive decline in people with T2D. Design changes to the future trial are provided.
Trial registration: ANZCTR 12614000222640; Registered 3/3/2014; First participant enrolled 26/6/2014, study
screening commenced 1/9/2014; Australian and New Zealand Clinical Trial Registry.
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Background
Worldwide there are over 35 million people living with
dementia, with numbers projected to reach close to 115
million by 2050 [1]. Dementia is the greatest cause of
disability and associated with significant decline in qual-
ity of life. Dementia was recently highlighted as a major
societal issue due to the absence of effective disease-
modifying medications [2]. Strategies for prevention in
people at high risk are therefore important in reducing
the current and future burden of dementia on the indi-
vidual and the health-care system.
Type 2 Diabetes (T2D) is regarded as one of the most
important modifiable risk factors for dementia [1]. T2D
is associated with a nearly two-fold increase in the risk
of incident dementia [3] and with accelerated rates of
cognitive decline [4]. The predominate cognitive
domains affected include executive function and
processing speed, and to a lesser degree verbal and visual
memory [5]. The pathways leading to cognitive decline
in T2D appear to be mixed with both neurodegeneration
[6, 7] and cerebrovascular disease [7, 8] playing roles.
Given the presence of multiple risk factors and patho-
physiological mechanisms (dysglycaemia, insulin resist-
ance, obesity, hypertension, physical inactivity) [9, 10]
contributing to T2D related dementia, therapeutic
approaches that can address multiple risk factors simul-
taneously are likely to provide the greatest benefits.
Structured exercise training for at least 3 to 6 months
has been demonstrated to improve glycaemic, metabolic,
inflammatory and vascular profiles in people with T2D
[11]. Exercise for animals has also been shown to
improve angiogenesis, synaptogenesis and neurogenesis
[12]. Although there is persuasive evidence from obser-
vational studies regarding the benefits of exercise for
cognitive health [13], results from human randomised
controlled trials (RCT) have been inconsistent in older
people [14–19]. A recent meta-analysis of studies of
exercise intervention trials in older adults suggests bene-
fits for cognition, for both aerobic and resistance training
[20]. However, a Cochrane review and a recent RCT found
no benefit for exercise in cognitively healthy older people
[14, 15]. Those with T2D represent a distinct high-risk
group who have a cluster of biological risk factors for
cognitive decline. They may therefore respond favourably
to risk factor optimization via a multi-modal exercise
program, but the relevant data are limited. A small study
of people with pre-diabetes or recently diagnosed diabetes
(n = 28) found that 6 months of aerobic training improved
executive function [21]. In an exploratory post-hoc ana-
lysis from the Lifestyle interventions and Independence
for Elders (LIFE) RCT (n = 415), a 24 month exercise
intervention resulted in better scores in global cognitive
function and delayed recall only in people with T2D [22].
To date, there has been no adequately powered trial that
has demonstrated the efficacy of exercise on cognitive
function and other measures of brain health in people
with T2D.
Prior to embarking on such a large scale trial, we con-
ducted a pilot RCT in people with T2D to: 1) determine
the feasibility (design, recruitment, screening, random-
isation, adherence, safety and retention) of a 6-month
multi-modal exercise training program compared with
control to preserve or improve cognition and brain
structure, and 2) provide an estimate of the effects of
the intervention on outcomes and MRI brain structure.
Methods
Study design
Cognition and Diabetes in Older Tasmanians – A pilot
RCT of exercise (CDOT-X) was a 6-month single blind
parallel RCT incorporating a supervised and progressive
multi-modal exercise program with blinded outcome
assessments. Participants with previously diagnosed T2D
were randomised to either: 1) a multi-modal aerobic and
resistance training (ART) program, or 2) a stretching/
gentle movement control group. Participants were ran-
domised by a central automated allocation procedure
(parallel groups stratified within two age strata of 50–64
and 65–75 years) after baseline assessment, based on
computer-generated random numbers ensuring alloca-
tion concealment. Assessment staff were blinded to ran-
domisation group. Participants were informed that the
study was designed to examine the difference between
two different types of exercise, but were unaware of the
nature of the alternative exercise program. All assess-
ments and exercise classes (the two study groups trained
at separate times) occurred at the Menzies Institute for
Medical Research, University of Tasmania. Brain MRI
scans were performed at the Royal Hobart Hospital,
Tasmania, Australia. The trial was registered with the
Australian New Zealand Clinical Trials Registry: ACTRN:
12,614,000,222,640 and was performed according to the
CONSORT 2010 extension to randomised pilot and feasi-
bility trials [23]. Ethics approval was from the Human
Ethics Committee Tasmania Network (H0013664) and writ-
ten informed consent was obtained from all participants.
Participants and eligibility criteria
Recruitment strategies included contacting participants
from a previous longitudinal study of brain health in
T2D (Cognition and Diabetes in Older Tasmanians
(CDOT) [7], advertising at the Diabetes Clinics at the
Royal Hobart Hospital, and by using Australian National
Diabetes Services Scheme listings, general advertising,
and social media . Eligibility was initially determined by
a telephone screening interview (for the inclusion and
exclusion criteria listed below). This was followed on a
separate day by a medical assessment (including medical
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history, medication use and an ECG) by a doctor and an
exercise stress test at the Menzies Institute for Medical
Research. During the test VO2max was collected using
the Bruce protocol and an exercise ECG and echocardio-
gram were performed. If the doctor had any concerns
about the participants results they were referred for a
cardiology review. Participants who passed these assess-
ments were asked to return on a separate day for the
clinic assessment and MRI scan.
Inclusion criteria
1) established T2D diagnosed by fasting blood glucose
≥7 mmol/L or 2 h post-prandial glucose ≥11.1 mmol/L
or HbA1C ≥ 6.5% according to current American
Diabetes Association Guidelines [24]; 2) age 50–75 years;
3) willingness and ability to participate in a structured
exercise program for 6-months, and 4) ability to partici-
pate in all cognitive testing.
Exclusion criteria
1) Severe orthopaedic or respiratory conditions that
would preclude participation in an exercise program, or
those with absolute contraindications to exercise accord-
ing to American College of Sports Medicine guidelines
[25]; 2) severe cardiovascular disease detected by an
exercise stress test as per Australian guidelines [26]; 3)
dementia (Telephone Interview for Cognitive Status
TICS–Modified score < 27/50); 4) known central
nervous system disorders that may have important
effects on cognitive function (e.g. intracranial tumour,
multiple sclerosis, Parkinson’s disease); 5) contra-
indication to MRI; 6) existing participation in structured
exercise greater than the equivalent of 30 min per week
at moderate intensity.
Aerobic and resistance training intervention
Participants in the intervention group were asked to
undertake a 6-month multi-modal exercise program
incorporating aerobic and progressive resistance training
(PRT) as this has been found to have the strongest bene-
fit on both cognition [18] and T2D markers such as glu-
cose control [27], as well as potentially benefiting brain
health through different signaling pathways [28]. It was
implemented by accredited exercise physiologists (AEP)
or physiotherapists, who supervised small groups (6–8
people) undertaking two one-hours supervised sessions
per week on non-consecutive days, supplemented by a
further one-hour per week unsupervised session at the
participant’s home or in the community with prescribed
aerobic exercise. Intensity of training relied on the Borg
Scale rating of perceived exertion (RPE; range 6 to 20)
[25]. Each supervised session consisted of approximately
30 min of moderate- to high-intensity PRT (3 sets of 8–12
reps at 14–17 ‘hard to very hard’ on the 20 point RPE
scale) of the upper and lower extremity exercises using
body weight, machine or free weights [29]. An aerobic
component of approximately 30 min consisted of station-
ary cycling, cross trainer, rower or treadmill walking start-
ing at a low-moderate intensity (RPE 12–13) and
progressively building to a moderate-vigorous intensity
(RPE 14–16) [26]. The program was individually tailored
to each participants ability and progressive intensity was
applied with increasing fitness to ensure safety recom-
mendations were met [26]. The 6-month program was
divided into six 4 weekly mesocycles and a final 2 week
mesocycle of progressing higher intensity. Within the
4 week cycle the final week was at a slightly lower inten-
sity (regeneration phase), before increasing intensity again
in the first week of the following mesocycle.
Control intervention
Participants randomised to the control arm received a 6-
month light intensity upper and lower limb stretching
and gentle movement program, which was also imple-
mented by AEPs and physiotherapists at a distinct time
to the intervention group. Participants attended two
one-hour supervised sessions per week, and carried out
one unsupervised session at home. These activities were
designed to provide the same amount of participative
involvement and socialization as the intervention group.
Both groups were provided with a participant man-
ual outlining the group specific exercise program as
well as motivational tips and safety advice (e.g. foot
inspection, measurement of blood glucose before and
after exercise).
Feasibility measures
Design
Ability and time required of study staff to co-ordinate
the recruitment, screening and clinic tasks; co-
ordination of exercise and control group classes; abil-
ity of participants to attend classes; any changes to
the study protocol.
Recruitment and screening
Time and number of people screened to enrol 50
participants.
Randomisation
Balance of characteristics in each group.
Adherence
Adherence in both groups assessed by attendance at the
supervised sessions. Percentages of classes attended/allo-
cated in each group. Home exercise training was assessed
by a participant exercise diary.
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Safety
The number and description of both serious (any admis-
sion to the department of emergency medicine or
hospitalization, life threatening event or results in per-
sistent or significant disability/incapacity or death) and
other adverse events by group. Serious adverse events
(including falls, injuries, hypoglycaemic events and foot
ulcers) were adjudicated by a Data Safety Monitor (an
independent academic General Practitioner) as not
related to the study, probably not related, unlikely but
possibly related or probably related to the study.
Retention
Number of participants that withdrew by group.
Outcome measures
Measurements were administered at baseline and 6-
months at the Menzies Institute for Medical Research,
apart from MRI scans. Clinics lasted approximately 3 h
and included breakfast. MRI scans occurred on a separ-
ate day at the Royal Hobart Hospital which is located
across the road from the Menzies Institute for Medical
Research and took approximately 1 h. At the 6 month
visit participants were asked not to tell assessment staff
which group they attended. All data (except MRIs) were
collected on teleform questionnaires, which were
scanned and transferred to a secure access database.
Brain MRI
The following acquisition protocols were used in a 3.0 T
GE Signa HDxt scanner: High-resolution 3-dimensional
T1 weighted spoiled gradient recalled (SPGR)
(TR = 6.732 ms, TE = 2.816 ms, flip angle =12°,
FOV = 225 mm, voxel size 1x1x1mm; fluid attenuated
inversion recovery (FLAIR, TR = 10,000 ms, TE = 121 ms,
FOV = 220 mm, flip angle = 90°, voxel size 0.4 × 0.4 and
4 mm); DTI using High Angular Resolution Diffusion
Imaging (HARDI) sequence with 64 gradient directions
(b = 2000s/mm2, TR = 7200 ms, TE = 105 ms,
FOV = 240 mm, voxel size (2.0.954 × 0.952.4 × 6.53 mm3)
and 1 b = 0 s/mm2 reference image. MRI pre-processing
and analyses were performed in the image analysis lab at
Monash University using well-established methods
blinded to age, sex and outcome measures. Brain struc-
tural outcome measures included total brain, white matter
and hippocampal volume and cortical thickness. The
Freesurfer 5.3 longitudinal pipeline [30] was used to
estimate cortical thickness and brain volume. Hippocampal
volumes were estimated using FSL FIRST [31] with the fol-
lowing additions to improve reliability on older participants.
The T1 weighted scans were nonlinearly transformed to
MNI space using the transformations estimated by the
SPM12 unified segmentation procedure. FIRST was applied
to the transformed image and the resulting segmentation
transformed back to native space for volume estimation.
The FSL TBSS [32] preprocessing pipeline was used to
compute a white matter skeleton of the whole brain. Mean
white matter microstructural measures, fractional anisot-
ropy (FA) and mean diffusivity (MD), were computed for
the skeleton. Cerebrovascular white matter hyperintensities
were delineated as previously described [33], with the statis-
tical classifier stage replaced by a manual selection. Lesion
masks were used to correct Freesurfer errors caused by
hypointensities on T1-weighted scans.
Cognitive function
The following tests were administered: 1) The Victoria
Stroop test (interference score C-D) [34]; 2) The Trail
Making Test (shifting score B-A); 3) The Digit Symbol
Coding Test (DSC) [35]; The digit span subtest of the
Wechsler Adult Intelligence Scale – Third Edition
(WAIS-III) [35]; Controlled Oral Word Association Test
(COWAT) [36]; The three part Hopkins Verbal Learning
Test – Revised (HVLT) [36] and the Rey Complex
Figure copy and delay [36]. These tests were chosen as
they are sensitive to the effects of T2D [5], and mild
cognitive changes that affect daily functioning, and have
previously been used in intervention studies in T2D to
preserve cognition [37]. In post-hoc analysis we used the
cognitive measures that showed improvement in the
ART group compared to the control group to calculate a
global composite score similar to prior studies [38, 39].
Other measures
The following measures were also assessed: 1) Brachial
and central blood pressure using the IEM Mobil-O-
Graph with 8 automated readings taken seated every
2 min and then averaged; 2) Fasting blood tests: blood
glucose, insulin, HbA1C (baseline only) using standard
techniques; 3) Physical fitness: VO2max obtained using
the Bruce treadmill protocol measured on a separate day
to the other clinic assessments; 4) Knee extension
strength (kg) using a spring gauge from the Short
Physiological Performance battery [40] and grip strength
using a Jamar digital hand dynamometer (kg); 5)
Anthropometrics: Height and weight to calculate BMI
and waist circumference using standard measures; and
6) Health and lifestyle: A standardised questionnaire was
used to collect data on health, medical history and
medication use.
Statistical analysis
A consort diagram was used to summarise screening,
recruitment and study retention. Descriptive statistics
were used to describe the characteristics of the sample
by group (means [SD], percentages and frequencies) as
well as exercise adherence and adverse events. Cognitive
and brain measure at baseline and follow-up were
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presented as means and SE and change over time as
means and 95%CI by group. Random intercept linear
mixed models with maximum likelihood estimation
adjusted for age, sex and education (and intracranial
volume for MRI measures) were performed to determine
if there were any differences in the slope between the
groups for the change over time. Correlations coeffi-
cients were used to examine associations between
change in mechanistic variables (VO2max, knee extension
strength, waist circumference, central and brachial blood
pressure, and fasting glucose and insulin levels) and
change in a cognitive global score. As this is a pilot
study we have not provided P-values or controlled for
Type 1 errors, but have included mean changes with
95% confidence intervals (CI) for the within group
changes and the net between group differences for the
change over time to provide an indication of the magni-
tude and direction of any effect [41].
Results
Design
Coordination of recruitment, screening, clinic assess-
ments (3–3.5 h per person) and the interventions were
performed without any changes to the protocol during
the pilot. Offering classes at multiple times worked well
with only one participant unable to attend the two
classes per week (see CONSORT diagram Fig. 1). The
class size of 6–8 participants in the intervention
group (1 h) and 8–10 participants in the control
group (1 h) was deemed essential to enable adequate
supervision to ensure safety and protocol adherence.
Trainers noted that an extra 15–20 min for new
participant orientation and for completing exercise
charts would be useful. Onsite parking was also
considered important by participants.
Recruitment, screening and randomisation
One-hundred and fourteen participants were screened
for eligibility of whom 50 (mean [SD] age 66.2 [4.9]
years; 48% women) were randomised and assigned to
the intervention or control group over an 8-month
period (September 2014 to May 2015). Reasons for
exclusion are shown in Fig. 1 and group characteristics
are summarized in Table 1.
Retention: Of the 50 participants, 47 (94%) remained
in the study at the 6-month follow-up. Reasons for with-
drawal (ART n = 2; control n = 1) were unexpected
travel interstate (n = 1), carer for family member (n = 1)
or inability to contact (n = 1). Of the cognitive assess-
ments one person was colour blind and could not
complete the Stroop test. Three people had missing
components of the HVLT (delay and recognition
[n = 1]; recognition [n = 2]). Of the 47 participants
who returned at 6 months, 1 further participant was
unable to complete the MRI scan due to new claus-
trophobia. Adherence: Exercise class attendance for
the ART group was 79% and for the controls 75%.
Seventy five percent of participants adhered to the
60 min of home exercise.
Fig. 1 Consort flow diagram
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Brain MRI
Table 2 provides the unadjusted and adjusted means for
brain MRI measures at baseline and 6 months, the mean
change over time in each group, and net between group
differences for the change over time (with 95% CI).
Compared with the controls, the ART group showed
improvements in white matter integrity (FA), hippocampal
and total brain volumes, and less decline in white matter
volume over the 6-month period.
Cognition
Unadjusted and adjusted means for cognitive measures
by group at baseline and 6 months, and the mean
change and net between group differences (with 95% CI)
are also presented in Table 2. In post-hoc analyses we
also created a global cognitive score by forming a com-
posite of these tests calculated as z scores standardized
to the baseline mean and SD [4, 14] (Table 2). Compared
with controls, the ART group showed improvements in
the global cognitive score, Stroop C-D, Trails A-B, DSC,
Hopkins intermediate and recognition scores, COWAT-
word and Rey Complex Copy tests. Table 3 shows the
correlations between change in the mechanistic variables
and change in the cognitive composite scores by group.
The strongest association was seen between an increase
in fitness (VO2max) and increase in global cognition
(r = 0.42), with a weaker association for reduction in
central systolic blood pressure (r = −0.15). An associ-
ation between global cognition and fasting blood glucose
(r = 0.13) was in the opposite direction than expected.
Safety: adverse events
There were two serious adverse events in the interven-
tion group and four in the control (Table 4). All serious
adverse events were ruled by the Data Safety Monitor as
unlikely or not due to the intervention. One participant
suffered a myocardial infarction 1 week after finishing
the ART program and this was ruled unlikely but
possibly due to the intervention. There were nine other
adverse events recorded including two falls in the
control group (in the same participant; one fall in the
class); one person with symptomatic postural drop during
the exercise tolerance test and six (5 ART and 1 control
group) with musculoskeletal complaints of which all
resolved within a few weeks or specific exercises associ-
ated with pain were modified.
Discussion
The present pilot study has demonstrated feasibility (in
study design, recruitment, screening, randomisation,
adherence, safety reporting and retention, and effect size
estimates) for a subsequent definitive RCT to test
whether a multi-modal exercise program incorporating
aerobic plus resistance training can provide benefits to
cognition and brain structure in people with T2D.
Recruitment procedures resulted in 114 people fulfilling
the inclusion and exclusion criteria volunteering over
8 months (approximately 14 participants per month). A
telephone screening procedure was successful in deter-
mining eligibility and availability including identifying
those who were too busy, lived too far away or who were
Table 1 Baseline characteristics of the total sample, ART and control group
Characteristics, mean, SD unless indicated Total (n = 50) ART intervention (n = 26) Control (n = 24)
Age, years 66.2 4.91 65.3 5.0 67.1 4.8
Female, n (%) 24 (48.0) 15 (57.7) 9 (37.5)
Body mass index, kg/m2 30.9 4.87 31.1 5.2 30.7 4.7
Years of education, n (%) 12.6 (3.4) 13.3 (3.6) 11.8 (3.1)
HbA1c, % 6.8 1.1 6.8 1.2 6.8 1.0
Fasting glucose, mmol/L 8.3 2.6 8.5 3.0 8.1 2.1
Fasting insulin, mU/L 19.1 20.6 17.8 19.5 20.6 22.2
Systolic blood pressure, mmHg 117.6 12.2 117.2 10.1 118.0 14.5
Diastolic blood pressure, mmHg 77.6 10.4 77.9 8.0 77.3 12.8
VO2max, L/min 21.6 4.8 22.0 5.1 21.1 4.5
Self-reported medical history
Hypertension, n (%)a 44 (88.0) 21 (80.8) 23 (95.8)
Insulin use, n (%) 10 (20.0) 6 (23.1) 4 (16.7)
High Cholesterol, n (%) 42 (84.0) 21 (80.8) 21 (87.5)
Myocardial infarction, n (%)* 2 (4.1) 0 (0.0) 2 (8.3)
Years since Type 2 Diabetes diagnosis 12.6 7.1 11.8 7.6 13.3 6.5
ART aerobic and resistance training, HbA1c glycated hemoglobin, SPPB short physical performance battery
*one participant had missing data
aHypertension: self-reported hypertension or SBPmmHg > 140
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unable to participate for other health reasons. The face-
to-face medical assessment and exercise stress test were
useful in excluding a further seven people due to high
cardiovascular risk. The rate of recruitment was also
perceived by trainers as optimal in order to allocate
sufficient time for orientating new participants to
exercises. Taking into account the relatively small
sample size, baseline characteristics appeared balanced
between groups except for sex and prior myocardial
infarction. It is likely that a larger sample size would
further improve the comparability of the intervention
and control groups.
The intervention group combined aerobic and resist-
ance training, which is based on superior outcomes pre-
viously observed with cognition [18] and T2D markers
such as blood glucose control [27], as well as potentially
benefiting brain health through different signaling
pathways [28]. The control group carried out stretches
and gentle movements designed to provide the same
amount of socialization as the intervention group. The
adherence for the two centre-based sessions was similar
(79% in the intervention and 75% for the control group),
which suggests that participants accepted the outcome
of randomisation. The retention rate (94%) was compar-
able or better than prior studies described in a meta-
analysis [42] with only three people not returning for
follow-up. We established the need for small exercise
groups to ensure the program was tailored according to
each individual, with close supervision by a trainer to
enhance motivation, ensure correct exercise technique
and appropriate blood glucose monitoring. Six serious
adverse events (all in different participants) were deemed
not or unlikely due to the intervention. Of other adverse
events, there was one fall without injury that occurred in
Table 2 Mean baseline and 6-month scores for cognitive function and brain MRI and the mean within group changes and net
between groups differences for the change over time
Outcome ART group Control Group Between-group
differenceaBaseline 6-months Change Baseline 6-months Change
Mean (SE) Mean (SE) Mean (95% CI) Mean (SE) Mean (SE) Mean (95%CI) Mean (95% CI)
Cognitive global score 0.06 0.11 0.20 0.11 0.14 0.02,0.27 −0.06 0.12 −0.08 0.12 −0.01 −0.14,0.12 0.16 −0.02, 0.34
RCF copy 27.6 0.9 27.4 0.9 −0.2 −1.8, 1.5 26.2 0.9 25.9 0.9 −0.3 −2.03,1.4 0.2 −2.1, 2.6
RCF delay 14.8 1.0 16.0 1.0 1.3 −0.2, 2.8 13.9 1.0 15.5 1.00 1.6 0.03, 3.1 −0.3 −2.5, 1.8
Stroop C-D 16.7 1.8 12.9 1.9 −3.8 −7.1, −0.5 20.1 1.9 18.3 1.9 −1.8 −5.1, 1.6 −2.1 −6.7, 2.6
Trails B-A 40.2 4.5 31.5 4.7 −8.7 −17.9,0.5 38.2 4.7 33.8 4.8 −4.3 −13.8,5.1 −4.4 −17.7, 9.0
DSC 58.6 2.6 60.8 2.6 2.2 0.2, 4.2 56.1 2.7 56.1 2.7 0.0 −2.1,2.1 2.3 −0.6, 5.2
Digit span 19.2 0.7 18.2 0.7 −1.0 −1.9,-0.1 19.9 0.7 20.6 0.7 0.7 −0.2,1.6 −1.7 −3.0, −0.5
Hopkins I 26.1 0.9 26.8 0.9 0.7 −0.9,2.2 27.0 0.9 27.3 1.0 0.3 0.-1.3,1.9 0.4 −1.9, 2.7
Hopkins D 9.4 0.4 9.5 0.5 0.1 −0.7,0.9 9.0 0.5 9.2 0.5 0.2 −0.6, 1.0 −0.1 −1.2, 1.0
Hopkins R 10.7 0.2 10.5 0.2 −0.2 −0.7,0.4 10.7 0.2 10.1 0.2 −0.6 −1.1,-0.0 0.5 −0.3, 1.2
COWAT word 40.7 2.5 43.7 2.5 3.1 0.4,5.7 38.3 2.6 39.7 2.6 1.4 −1.3,4.1 1.7 −2.0, 5.4
COWAT Category 21.0 0.9 20.1 0.9 −0.9 −2.6,0.8 18.7 1.0 19.3 1.0 0.6 −1.1,2.4 −1.5 −3.9, 1.0
MRI brain
Total brain 1128.5 28.6 1130.1 28.6 1.6 −2.3,5.5 1176.14 28.55 1175.7 28.6 −0.5 −4.4,3.4 1.9 −3.7,7.4
White matter 742.2 34.7 741.1 34.7 −1.1 −9.9,7.7 814.46 34.66 808.7 34.7 −5.8 −14.6,3.1 4.3 −8.4,17.0
C-thickness 3.8 0.1 3.8 0.1 0.0 −0.1,1.1 3.43 0.13 3.5 0.1 0.1 −0.0,0.2 −0.0 −0.2,0.1
Hippocampal 6.9 0.1 7.0 0.1 0.10 −0.01,0.20 7.2 0.14 7.1 0.1 −0.02 −0.12,0.08 0.13 −0.03, 0.29
White FA 0.408 0.004 0.412 0.004 0.002 −0.002,0.006 0.406 0.004 0.399 .005 −0.007 −0.012,-0.003 0.009 0.003, 0.016
White MD 0.001 0.000 0.001 0.000 −0.000 −0.000,0.000 0.001 0.000 0.001 0.000 −0.000 −0.000,0.000 −0.000 0.000,0.000
RCF Rey Complex Figure, DSC digit symbol coding, Hopkins (I-immediate, D delay, R recall), COWAT Controlled Oral Word Association Test, C-thickness
cortical thickness, FA fractional anisotrophy, MD mean diffusion, Stroop and Trails:higher scores poorer performance
aadjusted for age, sex and education (brain measures also adjusted for intracranial volume)
Table 3 Pearson’s correlations between change in mechanistic variables and change in global cognitive function in all
participants combined
Waist
circumference
VO2max Brachial
SBP
Brachial
DBP
Central
SBP
Central
DBP
Knee
strength
Fasting
glucose
Fasting
insulin
Grip
strength
Global cognitive score 0.08 0.45 −0.08 −0.10 −0.15 −0.05 0.03 0.13 0.01 0.11
SBP systolic blood pressure, DBP diastolic blood pressure
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the control group. Five participants also reported mus-
culoskeletal pain in the intervention group and one in
the control group, all of which were pre-existing or
resolved with expectant management. It is difficult to
compare these figures to other trials as a prior report of
adverse events in 121 exercise RCT found that in
general, adverse events are poorly reported [43]. In order
of prevalence, musculoskeletal complaints, falls and
cardiovascular events were most common [43]. Older
people and those with T2D are more likely to have con-
ditions such as arthritis and cardiovascular disease. In
light of this, we took precautions by performing a med-
ical screen and exercise stress test before randomisation,
providing participants with a booklet of the training pro-
gram and exercise precautions, as well as having a 4 week
light intensity preparatory training phase at the start of
the program, and one easier week in every 4 week cycle.
However, a further individualized initial orientation and
assessment at the beginning of the program with the
trainer may also be worthwhile.
As this was a pilot study, no a priori power estima-
tions were performed, and no tests of efficacy or statis-
tical significance are provided for the between group
differences or change over time in brain or cognitive
measures as false positives and false negatives are likely.
However, 95% confidence interval were provided to give
information about the magnitude and direction of an
effect [23, 41]. Nevertheless, our between-group differ-
ence for the change over time in the global cognitive
score was similar to the change (mean decrease 0.18 SD)
observed over 5-years in a previous observational study
in people with T2D [4]. These data suggest that a global
composite score can be a sensitive primary outcome
measure in a larger definitive exercise trial, avoiding
issues related to multiple primary outcome measures
[44]. Of the individual cognitive scores, all but the Rey
Complex Figure delay, Digit span, Hopkins Delay and
the COWAT Categories tests favored the intervention
group. We included structural brain and cognitive mea-
sures that have previously been shown to be sensitive to
T2D related cognitive impairment [5, 7, 45]. Few prior
RCT have included brain MRI as well as measurements
to study underlying pathways influenced by exercise. In
the few brain imaging studies of people without T2D, as
little as 6–12 months of exercise has been shown to lead
to measurable increases volume of the hippocampus
[46, 47]. Our pilot data are broadly consistent with
these findings and suggest that total, white matter
and hippocampal volume, as well as white matter
integrity might benefit from an ART program. This
needs to be confirmed in a larger trial.
Although we foresee no major changes to the protocol
in a larger study, there are a number of considerations in
the design and conduct of future such trials. Firstly, 12
participants did not complete the VO2max test at follow-
up. Although we did not record the reason for this,
wearing a mask for this test and exercising to maximum
levels may have caused discomfort to some participants.
Sub-maximal tests that reliably estimate VO2max may be
easier to complete in future trials. Secondly, although
there was no indication that assessment staff were aware
of group allocation, we did not formally evaluate blinding
such as by asking blinded study staff which group that
thought participants were in. Thirdly, exercise trainers
indicated that heart rate monitoring would assist in asses-
sing intensity of aerobic exercise training over and above
the RPE scale. Fourthly, the treatment period was rela-
tively short. The optimum length of the intervention that
is required to prevent long-term cognitive decline is
unknown. Prior studies have reported benefits of both
kinds of exercise (aerobic and resistance) on blood pres-
sure, glycaemic control, insulin sensitivity, and fat mass
within 3–6 months [11]. A meta-analysis of exercise for
cognitive function in older adults found the largest bene-
fits with 3–12 months following aerobic plus resistance
training [18]. However, many of the benefits of exercise
may disappear after a program is stopped. Encouragingly,
one study reported that a 24-week walking program was
efficacious in improving cognition in older people with
MCI one-year post intervention [19]. This suggests that a
short-term (6-months) program may boost cognitive
reserve over the longer term. A larger definitive study
based on this pilot is planned to incorporate and
evaluate a 12-month phase designed to assist partici-
pants incorporate the program into real world home
or community exercise programs. Finally it is possible
that some medications such as insulin therapy and
the number of adverse events may influence results.
These should be considered in the statistical plan and
power calculations of a future study.
Table 4 Participants reporting adverse events
Total Intervention Control
Serious adverse events 6 2 4
Cardiac problema 2 1 1
High blood pressurea 1 0 1
Joint surgerya 1 1 0
Gall bladdera 1 0 1
Allergyb 1 0 1
Important adverse events 9 5 4
Fall 2 0 2c
Musculoskeletal pain 6 5 1
Symptomatic postural drop during ETT 1 0 1
ETT exercise tolerance test
aRequired hospitalization
brequired Emergency Department admission
cBoth in the same participant
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In addition to the above considerations there are other
limitations to the design of our study. The large number
of cognitive tests may have led to fatigue and a decline
in performance. However the order of tests was similar
for all participants. The lack of follow-up over longer
periods means that we were unable to determine longer
term dropout rates, effects on cognition or conversion
to dementia. It is possible that some participants in the
control group may have started to exercise, but it is
unlikely that they took up training at the intensity
performed by the intervention group. They also attended
the control classes twice a week which would have left less
time to take up another new exercise program. It is
possible that the control class may also have provided
cognitive benefits, reducing the differences between
groups. Although the combination of aerobic and resist-
ance training may provide additional benefit, a four armed
study (aerobic, resistance, aerobic and resistance, control)
would be required to tease out their individual effects.
Finally, some participants were from the longitudinal
CDOT study which may limit generalizability. However,
these people are well characterized and were also
recruited from the Australian National Diabetes
Service Scheme.
Conclusion
In conclusion, the present pilot study demonstrates
strong feasibility in terms of design, recruitment,
screening, adherence, safety and retention to a multi-
modal exercise program. A larger definitive trial to
determine if exercise can delay or prevent cognitive
decline in this high-risk group is now required. A
delay in just 1 year of the onset of dementia may
result in 9.2 million fewer cases globally [48].
Acknowledgements
Not applicable
Funding
Alzheimers Australia Research Foundation Grant No. CF13/3559.
Availability of data and materials
The datasets used and/or analysed during the current study are available
from the corresponding author on reasonable request.
Authors’ contributions
1. MC, RD, JS, DB, TG, MN, RB, MS, TP, LB and VS made substantial
contributions to conception and design, or acquisition of data, or analysis
and interpretation of data; 2. MC, RD, JS, TD, MN, RB, LB, TP, VS been
involved in drafting the manuscript or revising it critically for important
intellectual content; 3. MC, RD, JS, DB, TD, TG, MN, RB, MS, TP, LB, VS have
given final approval of the version to be published. Each author should have
participated sufficiently in the work to take public responsibility for
appropriate portions of the content; and 4. MC, LB and VS agreed to be
accountable for all aspects of the work in ensuring that questions related to
the accuracy or integrity of any part of the work are appropriately
investigated and resolved.
Ethics approval and consent to participate
Ethics approval was from the Human Ethics Committee Tasmania Network
(H0013664) and written informed consent was obtained from all participants.
Consent for publication
Not applicable
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Menzies Institute for Medical Research Tasmania, University of Tasmania, 17
Liverpool Street, Hobart, Tasmania, Australia. 2Stroke and Aging Research
Group, Department of Medicine, Southern Clinical School, Monash University,
Clayton, Victoria, Australia. 3Institute for Physical Activity and Nutrition (IPAN),
School of Exercise and Nutrition Sciences, Faculty of Health, Deakin
University, Melbourne, Victoria, Australia. 4Medical School, Faculty of Health
and Medical Sciences, University of Western Australia Fremantle Hospital,
Fremantle, Western Australia, Australia. 5Murdoch Children’s Research
Institute, Royal Children’s Hospital, Melbourne, Australia. 6Peninsula Clinical
School, Central Clinical School, Monash University, Melbourne, Victoria,
Australia. 7Department of Medicine, Frankston Hospital, Peninsula Health,
Melbourne, Victoria, Australia.
Received: 13 July 2017 Accepted: 8 October 2017
References
1. Alzheimer's Disease International: World Alzheimer report 2014. London.
Alzheimers Disease International; 2014. https://www.alz.co.uk/research/
WorldAlzheimerReport2014.pdf.
2. G8 Health and Science Ministers. G8 dementia summit declaration. In:
Edited by Gov UK, editor. RDD/10495; 2013.
3. Cheng G, Huang C, Deng H, Wang H. Diabetes as a risk factor for dementia
and mild cognitive impairment: a meta-analysis of longitudinal studies.
Intern Med J. 2012;42(5):484–91.
4. Nooyens AC, Baan CA, Spijkerman AM, Verschuren WM. Type 2 diabetes
and cognitive decline in middle-aged men and women: the Doetinchem
cohort study. Diabetes Care. 2010;33(9):1964–9.
5. Palta P, Schneider AL, Biessels GJ, Touradji P, Hill-Briggs F. Magnitude of
cognitive dysfunction in adults with type 2 diabetes: a meta-analysis of six
cognitive domains and the most frequently reported neuropsychological
tests within domains. J Int Neuropsychol Soc. 2014;20(3):278–91.
6. Moran C, Beare R, Phan TG, Bruce DG, Callisaya ML, Srikanth V. Alzheimer's
disease neuroimaging I: Type 2 diabetes mellitus and biomarkers of
neurodegeneration. Neurology. 2015;85(13):1123–30.
7. Moran C, Phan TG, Chen J, Blizzard L, Beare R, Venn A, Munch G, Wood
AG, Forbes J, Greenaway TM, et al. Brain atrophy in Type 2 diabetes:
regional distribution and influence on cognition. Diabetes Care.
2013;36(12):4036–42.
8. Qiu C, Sigurdsson S, Zhang Q, Jonsdottir MK, Kjartansson O, Eiriksdottir G,
Garcia ME, Harris TB, van Buchem MA, Gudnason V, et al. Diabetes, markers
of brain pathology and cognitive function: the age, gene/environment
susceptibility-Reykjavik study. Ann Neurol. 2014;75(1):138–46.
9. Biessels GJ, Strachan MW, Visseren FL, Kappelle LJ, Whitmer RA. Dementia
and cognitive decline in type 2 diabetes and prediabetic stages: towards
targeted interventions. Lancet Diabetes Endocrinol. 2014;2(3):246–55.
10. Callisaya ML, Moran C, Srikanth VK. Type 2 diabetes mellitus as a causal
factor for dementia – is there sufficient evidence from interventional
studies? Australian Epidemiologist. 2013;20:1.
11. Thomas DE, Elliott EJ, Naughton GA. Exercise for type 2 diabetes mellitus.
Cochrane Database Syst Rev. 2006;3:CD002968.
12. van Praag H, Shubert T, Zhao C, Gage FH. Exercise enhances learning and
hippocampal neurogenesis in aged mice. J Neurosci. 2005;25(38):8680–5.
13. Brown BM, Peiffer JJ, Martins RN. Multiple effects of physical activity on
molecular and cognitive signs of brain aging: can exercise slow
Callisaya et al. BMC Geriatrics  (2017) 17:237 Page 9 of 10
neurodegeneration and delay Alzheimer's disease? Mol Psychiatry.
2013;18(8):864–74.
14. Sink KM, Espeland MA, Castro CM, Church T, Cohen R, Dodson JA, Guralnik
J, Hendrie HC, Jennings J, Katula J, et al. Effect of a 24-month physical
activity intervention vs health education on cognitive outcomes in
sedentary older adults: the LIFE randomized trial. JAMA. 2015;314(8):781–90.
15. Young J, Angevaren M, Rusted J, Tabet N. Aerobic exercise to improve
cognitive function in older people without known cognitive impairment.
Cochrane Database Syst Rev. 2015;4:CD005381.
16. Fiatarone Singh MA, Gates N, Saigal N, Wilson GC, Meiklejohn J, Brodaty H,
Wen W, Singh N, Baune BT, Suo C, et al. The Study Of Mental and
Resistance Training (SMART) study-resistance training and/or cognitive
training in mild cognitive impairment: a randomized, double-blind, double-
sham controlled trial. J Am Med Dir Assoc. 2014;15(12):873–80.
17. Gates N, Fiatarone Singh MA, Sachdev PS, Valenzuela M. The effect of
exercise training on cognitive function in older adults with mild cognitive
impairment: a meta-analysis of randomized controlled trials. Am J Geriatr
Psychiatry. 2013;21(11):1086–97.
18. Colcombe S, Kramer AF. Fitness effects on the cognitive function of older
adults: a meta-analytic study. Psychol Sci. 2003;14(2):125–30.
19. Lautenschlager NT, Cox KL, Flicker L, Foster JK, van Bockxmeer FM, Xiao J,
Greenop KR, Almeida OP. Effect of physical activity on cognitive function in
older adults at risk for Alzheimer disease: a randomized trial. JAMA.
2008;300(9):1027–37.
20. Northey JM, Cherbuin N, Pumpa KL, Smee DJ, Rattray B. Exercise
interventions for cognitive function in adults older than 50: a
systematic review with meta-analysis. Br J Sports Med. 2017;
doi: 10.1136/bjsports-2016-096587.
21. Baker LD, Frank LL, Foster-Schubert K, Green PS, Wilkinson CW, McTiernan A,
Cholerton BA, Plymate SR, Fishel MA, Watson GS, et al. Aerobic exercise
improves cognition for older adults with glucose intolerance, a risk factor
for Alzheimer's disease. J Alzheimers Dis. 2010;22(2):569–79.
22. Espeland MA, Lipska K, Miller ME, Rushing J, Cohen RA, Verghese J,
McDermott MM, King AC, Strotmeyer ES, Blair SN, et al. Effects of physical
activity intervention on physical and cognitive function in sedentary adults
with and without diabetes. J Gerontol A Biol Sci Med Sci. 2017;72(6):861–6.
23. Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L,
Lancaster GA. group Pc: CONSORT 2010 statement: extension to
randomised pilot and feasibility trials. BMJ. 2016;355:i5239.
24. American Diabetes A. (2) Classification and diagnosis of diabetes. Diabetes
Care. 2015;38 Suppl:S8–S16.
25. Medicine ACoS: ACSMs guidelines of exercise testing and prescription, 9
edn. Philadelphia: Lippincott Williams & Wilkins; 2014.
26. Hordern MD, Dunstan DW, Prins JB, Baker MK, Singh MA, Coombes JS.
Exercise prescription for patients with type 2 diabetes and pre-diabetes: a
position statement from exercise and sport science Australia. J Sci Med
Sport. 2012;15(1):25–31.
27. Church TS, Blair SN, Cocreham S, Johannsen N, Johnson W, Kramer K, Mikus
CR, Myers V, Nauta M, Rodarte RQ, et al. Effects of aerobic and resistance
training on hemoglobin A1c levels in patients with type 2 diabetes: a
randomized controlled trial. JAMA. 2010;304(20):2253–62.
28. Cassilhas RC, Lee KS, Fernandes J, Oliveira MG, Tufik S, Meeusen R, de Mello
MT. Spatial memory is improved by aerobic and resistance exercise through
divergent molecular mechanisms. Neuroscience. 2012;202:309–17.
29. Gianoudis J, Bailey CA, Ebeling PR, Nowson CA, Sanders KM, Hill K, Daly RM.
Effects of a targeted multimodal exercise program incorporating high-speed
power training on falls and fracture risk factors in older adults: a community-
based randomized controlled trial. J Bone Miner Res. 2014;29(1):182–91.
30. Reuter M, Rosas HD, Fischl B. Highly accurate inverse consistent registration:
a robust approach. NeuroImage. 2010;53(4):1181–96.
31. Patenaude B, Smith SM, Kennedy DN, Jenkinson M. A Bayesian model of
shape and appearance for subcortical brain segmentation. NeuroImage.
2011;56(3):907–22.
32. Smith SM, Jenkinson M, Johansen-Berg H, Rueckert D, Nichols TE, Mackay
CE, Watkins KE, Ciccarelli O, Cader MZ, Matthews PM, et al. Tract-based
spatial statistics: voxelwise analysis of multi-subject diffusion data.
NeuroImage. 2006;31(4):1487–505.
33. Beare R, Srikanth V, Chen J, Phan TG, Stapleton J, Lipshut R, Reutens D.
Development and validation of morphological segmentation of age-related
cerebral white matter hyperintensities. NeuroImage. 2009;47(1):199–203.
34. Spreen O, Strauss E. A compendium of neuropsychological tests.
Administration, norms, and commentary. 2nd ed. New York: Oxford
University Press; 1998.
35. Weschler D. Weschler Adult Intelligence Scale. New York: Psychological
Corporation; 1997.
36. Lezak M. Neuropsychological assessment. 3rd ed. New York: Oxford
University Press; 1995.
37. Williamson JD, Launer LJ, Bryan RN, Coker LH, Lazar RM, Gerstein HC, Murray
AM, Sullivan MD, Horowitz KR, Ding J, et al. Cognitive function and brain
structure in persons with type 2 diabetes mellitus after intensive lowering
of blood pressure and lipid levels: a randomized clinical trial. JAMA Intern
Med. 2014;174(3):324–33.
38. Valls-Pedret C, Sala-Vila A, Serra-Mir M, Corella D, de la Torre R, Martinez-
Gonzalez MA, Martinez-Lapiscina EH, Fito M, Perez-Heras A, Salas-Salvado J,
et al. Mediterranean diet and age-related cognitive decline: a randomized
clinical trial. JAMA Intern Med. 2015;175(7):1094–103.
39. Barnes DE, Santos-Modesitt W, Poelke G, Kramer AF, Castro C, Middleton LE,
Yaffe K. The mental activity and eXercise (MAX) trial: a randomized
controlled trial to enhance cognitive function in older adults. JAMA Intern
Med. 2013;173(9):797–804.
40. Lord SR, Menz HB, Tiedemann A. A physiological profile approach to falls
risk assessment and prevention. Phys Ther. 2003;83(3):237–52.
41. Leon AC, Davis LL, Kraemer HC. The role and interpretation of pilot studies
in clinical research. J Psychiatr Res. 2011;45(5):626–9.
42. Smith PJ, Blumenthal JA, Hoffman BM, Cooper H, Strauman TA, Welsh-Bohmer
K, Browndyke JN, Sherwood A. Aerobic exercise and neurocognitive
performance: a meta-analytic review of randomized controlled trials.
Psychosom Med. 2010;72(3):239–52.
43. Liu CJ, Latham N. Adverse events reported in progressive resistance
strength training trials in older adults: 2 sides of a coin. Arch Phys Med
Rehabil. 2010;91(9):1471–3.
44. Langbaum JB, Hendrix S, Ayutyanont N, Bennett DA, Shah RC, Barnes
LL, Lopera F, Reiman EM, Tariot PN. Establishing composite cognitive
endpoints for use in preclinical Alzheimer's disease trials. J Prev
Alzheimers Dis. 2015;2(1):2–3.
45. Reijmer YD, Leemans A, Brundel M, Kappelle LJ, Biessels GJ. Utrecht vascular
cognitive impairment study G: disruption of the cerebral white matter
network is related to slowing of information processing speed in patients
with type 2 diabetes. Diabetes. 2013;62(6):2112–5.
46. Colcombe SJ, Erickson KI, Scalf PE, Kim JS, Prakash R, McAuley E, Elavsky S,
Marquez DX, Hu L, Kramer AF. Aerobic exercise training increases brain volume
in aging humans. J Gerontol A Biol Sci Med Sci. 2006;61(11):1166–70.
47. Erickson KI, Voss MW, Prakash RS, Basak C, Szabo A, Chaddock L, Kim JS, Heo
S, Alves H, White SM, et al. Exercise training increases size of hippocampus
and improves memory. Proc Natl Acad Sci U S A. 2011;108(7):3017–22.
48. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the
global burden of Alzheimer's disease. Alzheimers Dement. 2007;3(3):186–91.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Callisaya et al. BMC Geriatrics  (2017) 17:237 Page 10 of 10
